Table 2.

Treatment characteristics

Treatment	Patients (n = 453)
	N	%
Resection of primary tumour
Breast-conserving (incl. follow-up resection)	299	66.0
Non-breast conserving (mastectomy/ablatio mammae)	130	28.7
Unknown	24	5.3
Radiotherapy received	354	78.1
Chemotherapy setting at enrolmenta
Neoadjuvant	58	12.8
Adjuvant	395	87.2
Taxane-based chemotherapy	275	60.7
Top chemotherapy regimenb
F + E/A + C±Tra	151	33.3
F + E/A + C+D ± Tra	102	22.5
E/A + C+D ± Tra	61	13.5
E/A + C+P ± Tra	49	10.8
Car + D±Tra	18	4.0
Other	72	15.1
Endocrine therapy received	285	62.9
Endocrine therapy
Aromatase inhibitors (AI) ± GnRH	120	26.5
Anti-oestrogen (AE)	96	21.2
Switch AI/AE	67	14.8
GnRH-analogue	2	0.4

AE anti-oestrogen, AI aromatase inhibitor, C cyclophosphamide, Car carboplatin, D docetaxel, E/A epirubicin/doxorubicin, F fluorouracil, GnRH gonadotropin-releasing hormone, P paclitaxel, Tra trastuzumab

^aOnly patients who had received (neo)adjuvant chemotherapy were included in the present analysis, because the subgroup of patients who had received endocrine treatment only was too small for a meaningful analysis

^bAt primary diagnosis